



SUPRIYA LIFESCIENCE LTD.

Creating true values that bind global health

August 14, 2025

To,

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400 001
Scrip Code: 543434

National Stock Exchange of India Limited
Exchange Plaza, Plot no. C/1, G Block,
Bandra-Kurla Complex
Bandra (E), Mumbai - 400 051
NSE Symbol: SUPRIYA

Dear Sir (s),

Subject: Newspaper Advertisement- Regulation 47 and Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In terms of Regulation 30 read with Schedule III and Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith newspaper advertisement published in Financial Express and Loksatta on Thursday, August 14, 2025, containing extract of Unaudited Financial Results for the quarter ended June 30, 2025.

You are requested to kindly take the same on record.

Thanking you,

Yours faithfully,

For Supriya Lifescience Limited

Prachi Sathe

Company Secretary & Compliance Officer

Corporate office : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX
CIN: L51900MH2008PLC180452 E-mail: supriya@supriyalifescience.com Website: www.supriyalifescience.com

Factory : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.- Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: factory@supriyalifescience.com

GOVT. RECOGNISED EXPORT HOUSE

TATA
TATA POWER
The Tata Power Company Limited
(Mundra Thermal Power Station - UMPP)
Tunda Vadh Road, Tunda Village, Mundra, Kutch, Gujarat
Reg. Office: Bombay House, 24 Homi Modi Street, Mumbai - 400 001

NOTICE INVITING EXPRESSION OF INTEREST

The Tata Power Company Limited hereby invites Expression of Interest (EOI) from eligible bidders for the following requirement:

- Supply & Installation of UPVC piping system and FRP storage Tank at ICHS Pump House (Ref.: 4100051989)
- Procurement of Aluminium enclosure for various size of Panel (REF: 4100052135)
- Supply, Installation and commissioning of Lead acid battery banks (REF: 4100052136)
- Services for Salvaging of burner tips for 830 MW Boiler of Tata Power, Mundra Ref 4100052194
- Supply of multipurpose fire tender (Cap 19 Ton) of Tata Power, Mundra Ref 4100052196

For prequalification requirements, tender fee, bid security etc., please visit Tender section of our website (URL: <https://www.tatapower.com/tender/tenders-listing>) and refer detailed Tender Notice for subject tender. Eligible bidders willing to participate in this tender may submit their Expression of Interest along with the Tender Fee latest by 25/08/2025.

URJA GLOBAL LIMITED
Regd. Office: 487/63, 1st floor, National Market, Peeragarhi, New Delhi - 110087 | CIN: L67120DL1992PLC048983
Website: www.urjaglobal.in | Email: info@urjaglobal.in
Ph. No. 11-25279143

Opening of Special Window for Re-lodgement of Transfer Requests of Physical Shares

Pursuant to SEBI Circular no. SEBI/HO/MIRSD/MIRSD-PoD/P/CIR/2025/97 dated July 02, 2025, a special window has been opened for a period of six months, from July 07, 2025 to January 06, 2026 for re-lodgement of transfer requests of physical shares which were originally lodged prior to April 01, 2019 but were returned/ rejected/ not unattended due to deficiencies in the documents/process/otherwise. All eligible requests during this period shall be processed in dematerialised mode only.

All transfer requests duly rectified and re-lodged during the aforesaid period will be processed through the transfer-cum-demat mode, i.e., the shares will be issued only in dematerialised form after transfer. The lodger(s) must have a demat account and provide the Client Master List (CML) along with the transfer documents, share certificate(s) and other necessary document(s) while lodging the documents for transfer with our RTA.

Shareholders who meet the above criteria and wish to avail the opportunity, are requested to contact our Registrar and Share Transfer Agent, M/s Alankit Assignment Limited at rta@alankit.com, contact No. 011-42541234, Address: 4E/2, Alankit House, Jhandewalan Extension, New Delhi 110055.

For URJA GLOBAL LIMITED
Sd/-
MOHAN JAGDISH AGARWAL
Managing Director
DIN: 07627568

Date: August 13, 2025
Place: New Delhi

Anthem
BioSciences[®]

ANTHEM BIOSCIENCES LIMITED

CIN: U24233KA2006PLC039703
Regd Office: No.49, F1 & F2, Canara Bank Road, Bommasandra Industrial Area, Phase I, Bommasandra, Bengaluru - 560 099
Tel: +91 080 6672 4000 | Email: investors.abl@anthembio.com | Website: www.anthembio.com

EXTRACT OF THE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(Amt in INR Mn)

Particulars	Consolidated Financial Results			
	Quarter ended		Year ended	
	June 30, 2025	June 30, 2024	March 31, 2025	March 31, 2024
Total Income from operations	5,402.09	3,385.94	18,445.53	14,193.70
Net profit for the period (Attributable to owners of the company) (before tax, exceptional and/or extraordinary items)	1,862.48	1,179.76	6,568.68	4,773.18
Net profit for the period before tax (Attributable to owners of the company) (after exceptional and/or extraordinary items)	1,862.48	1,179.76	6,568.68	4,773.18
Net profit for the period after tax (after exceptional and/or extraordinary items)	1,357.91	823.79	4,512.59	3,673.10
Total comprehensive income for the period [comprising profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,373.18	821.91	4,508.63	3,670.62
Equity share capital	1,123.22	1,118.15	1,118.15	1,118.15
Other Equity (excluding revaluation reserve) as at June 30, 2025	24,657.77	18,950.30	22,980.48	18,128.39
Earnings per share (nominal value of share Rs.2) (Not annualised)				
Basic (Rs):	2.43	1.47	8.07	6.47
Diluted (Rs):	2.42	1.47	8.04	6.47

(Amt in INR Mn)

Particulars	Standalone Financial Results			
	Quarter ended		Year ended	
	June 30, 2025	June 30, 2024	March 31, 2025	March 31, 2024
Total Income from operations	5,380.11	3,385.39	18,406.49	14,175.39
Net profit for the period (Attributable to owners of the company) (before tax, exceptional and/or extraordinary items)	1,989.38	1,217.06	7,114.23	4,847.73
Net profit for the period before tax (Attributable to owners of the company) (after exceptional and/or extraordinary items)	1,989.38	1,217.06	7,114.23	4,847.73
Net profit for the period after tax (after exceptional and/or extraordinary items)	1,483.40	853.36	5,061.88	3,747.81
Total comprehensive income for the period [comprising profit for the period (after tax) and Other Comprehensive Income (after tax)]	1,498.43	851.47	5,057.91	3,745.33
Equity share capital	1,123.22	1,118.15	1,118.15	1,118.15
Other Equity (excluding revaluation reserve) as at June 30, 2025	25,416.35	19,064.07	23,613.97	18,212.59
Earnings per share (nominal value of share Rs.2) (Not annualised)				
Basic (Rs):	2.65	1.53	9.05	6.61
Diluted (Rs):	2.64	1.53	9.01	6.61

Notes:

- The above results for the quarter and year ended June 30, 2025, of the Company have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on August 13, 2025.
- The full format of the quarter and year ended financial results along with the limited review report of the Statutory Auditors thereon are available on <https://www.anthembio.com/investors>

Place: Bangalore
Date: August 14, 2025

For ANTHEM BIOSCIENCES LIMITED
Sd/-
Ajay Bhardwaj
Managing Director & CEO
(DIN 00333704)

Adfactors 401/25

Nazara
Technologies Limited

CIN: L72900MH1999PLC122970
Regd. Office: 51-54, Maker Chambers 3, Nariman Point, Mumbai - 400021
Tel.: +91-22-40330800, Fax: +91-22-22810606, Email: investors@nazara.com, Website: www.nazara.com

EXTRACT FROM THE UN-AUDITED CONSOLIDATED AND STANDALONE FINANCIAL RESULTS OF NAZARA TECHNOLOGIES LIMITED FOR THE QUARTER ENDED JUNE 30, 2025

(₹ in Lakhs)

Sr. No.	Particulars	CONSOLIDATED				STANDALONE			
		Quarter Ended		Year to date		Quarter Ended		Year to date	
		30-06-2025	31-03-2025	30-06-2024	31-03-2025	30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited Refer No.3	Unaudited	Audited	Unaudited	Audited Refer No.3	Unaudited	Audited
1	Total Income from Operations	57,587	53,891	27,565	1,71,544	4,652	2,694	2,703	10,086
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	3,062	574	3,403	7,787	1,883	637	1,230	3,175
3	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary items)	5,134	407	2,362	5,096	2,761	404	963	2,804
4	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8,036	664	2,164	5,586	2,768	397	959	2,780
5	Equity Share Capital (Face Value of ₹ 4/- each)	3,705	3,505	3,062	3,505	3,705	3,505	3,062	3,505
6	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year				2,82,800				2,64,608
7	Earnings Per Share (of ₹ 4/- each) (for continuing and discontinued operations)								
	Basic (in ₹):	7.73	(0.22)	2.96	9.47	3.12	0.41	1.26	3.50
	Diluted (in ₹):	7.73	(0.22)	2.96	9.47	3.12	0.41	1.26	3.50

Notes:

- The Un-audited Financial Result for the quarter ended June 30, 2025 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at the meeting held on August 12, 2025. The Statutory Auditors of the Company have carried out "Limited Review" of the above results as per Regulation 33 of the SEBI (LODR) Regulations, 2015
- The above is an extract of the detailed format of quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (LODR) Regulations, 2015. The full format of the quarterly results are available on the Stock Exchange website (i.e. www.bseindia.com and www.nseindia.com) and on the Company's website (i.e. www.nazara.com)
- The figures of the quarter ended March 31, 2025 represent the balancing figures between audited figures in respect of the full financial year ended March 31, 2025 and the unaudited published year-to-date figures upto December 31, 2024 which were subjected to limited review.
- The Board of Directors in its meeting held on August 12, 2025 has approved, subject to shareholder's approval, the sub-division of the face value of shares from ₹ 4/- to ₹ 2/- fully paid equity shares, and the issue of 1 fully paid bonus equity shares of face value ₹ 2/- for every 1 fully paid equity share of face value ₹ 2/-.

For and on behalf of the Board of Directors of Nazara Technologies Limited
Sd/-
Nitish Mittersain
Jt. Managing Director & CEO
DIN: 02347434

Place: Mumbai
Date: August 13, 2025

Adfactors 375/25

NYKAA

FSN E-COMMERCE VENTURES LIMITED

CIN: L52600MH2012PLC230136
Regd. Office: 104, Vasan Udyog Bhavan, Sun Mill compound, Tulsi Pipe Road, Lower Parel, Mumbai-400013.
Email ID: investor-relation@nykaa.com

EXTRACT OF CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹ in crore, except per share data)

Sr. No.	Particulars	Quarter ended		Year ended	
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income	2,164.27	2,070.71	1,753.44	7,977.08
2	Profit before tax	43.71	39.55	22.08	127.45
3	Profit after tax	24.47	19.05	14.24	73.70
4	Share in loss of associate	-	-	(0.60)	(1.63)
5	Profit for the period	24.47	19.05	13.64	72.07
6	Total Comprehensive Income	24.59	16.89	13.64	67.76
7	Paid-up equity share capital Face value (In ₹)	1.00	1.00	1.00	1.00
8	Other Equity as shown in the Audited Balance sheet of previous year				1,015.35
9	Earnings per equity share of face value of ₹ 1/- each (not annualised)				
	Basic (In ₹)	0.08	0.07	0.03	0.23
	Diluted (In ₹)	0.08	0.07	0.03	0.23

Notes:

- The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the financial results are available on the Stock Exchange websites (www.bseindia.com and www.nseindia.com) and on company's website (www.nykaa.com).
- Financial results of FSN E-Commerce Ventures Limited (standalone):

(₹ in crore)

Sr. No.	Particulars	Quarter ended		Year ended	
		June 30, 2025	March 31, 2025	June 30, 2024	March 31, 2025
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Total Income	121.93	125.91	142.01	577.28
2	Profit before tax	17.44	20.20	23.93	97.29
3	Profit after tax	12.92	14.62	42.23	97.36

3 The above financial results have been reviewed and recommended by the Audit Committee and have been approved and taken on record by the Board of Directors at its meeting held on August 12, 2025.

4 The review as required under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 has been completed by the statutory auditors of the Company for the quarter ended June 30, 2025.

5 The above is an extract of the detailed format of financial results filed with the Stock exchanges under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015. The full format of the quarter ended June 30, 2025 are available on the Company's website at <https://www.nykaa.com/media/wysiwyg/uiTools/2025-8/outcome-of-board-meeting-on-financial-results-q1-fy-26.pdf> as well as on the website of the National Stock Exchange of India Limited and BSE Limited at www.nseindia.com and www.bseindia.com respectively. The same can be accessed by scanning the QR code provided below.

For and on behalf of Board of Directors of FSN E-Commerce Ventures Limited
Falguni Nayar
Executive Chairperson, CEO and Managing Director

Place: Mumbai
Date: August 12, 2025

Adfactors 376/25

SUPRIYA LIFESCIENCE LIMITED

CIN No: L51900MH2008PLC180452
207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063.
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED JUNE 30, 2025

(₹ In million)

Sr. No.	Particulars	Quarter ended	Quarter ended	Quarter ended	Year ended
		30-06-2025	31-03-2025	30-06-2024	31-03-2025
		Unaudited	Audited	Unaudited	Audited
1	Total revenue from Operations	1,450.74	1,841.09	1,606.26	6,964.85
2	Net Profit/(Loss) for the period (before Tax, Exceptional)	474.12	640.61	597.74	2,484.80
3	Net Profit/(Loss) for the period before Tax, (after Exceptional)	474.12	640.61	597.74	2,484.80
4	Net Profit/(Loss) for the period after Tax (after Exceptional)	347.90	503.82	446.44	1,879.58
5	Total Comprehensive income for the period (comprising Profit/(Loss) for the period (after Tax) and Other Comprehensive Income (after tax)	345.75	504.69	445.88	1,878.33
6	Equity Share capital	160.97	160.97	160.97	160.97
7	Other Equity	10,152.39	9,806.63	8,438.58	9,806.63
8	Earning per share (of ₹2/- each) (not annualized)				
	1. Basic	4.32	6.29	5.54	23.35
	2. Diluted	4.32	6.29	5.54	23.35

Notes:

- The Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 13, 2025. The Auditors of the Company have carried out limited review of the Unaudited Financial Results for the Quarter ended June 30, 2025.
- The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the websites (www.bseindia.com), (www.nseindia.com) and Company's website (www.supriyalifescience.com)

Place: Mumbai
Date: August 13, 2025

For Supriya Lifescience Limited
Sd/-
Dr. Satish Waman Wagh
Chairman and Whole Time Director
DIN: 01456982

Sustainability. Growth. Profitability.

Adfactors 384/25

